ResearcherZhejiang Provincial People's HospitalActive in the last 2 years

Xiao Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0008-0130-1418. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2025: 1 paper

Papers 1

STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer. Co-author DOI 10.1007/s00535-025-02291-3 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Ran Tao · 1 shared paper, 2025 · strength 0.26
- Paper STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer. DOI 10.1007/s00535-025-02291-3 ↗
Zongting Gu · 1 shared paper, 2025 · strength 0.26
- Paper STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer. DOI 10.1007/s00535-025-02291-3 ↗
Peng Nan · 1 shared paper, 2025 · strength 0.26
- Paper STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer. DOI 10.1007/s00535-025-02291-3 ↗
Wei Wang · 1 shared paper, 2025 · strength 0.26
- Paper STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer. DOI 10.1007/s00535-025-02291-3 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.